Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Daniel J LovellHermine I BrunnerAndreas O ReiffLawrence JungKaterina JarosovaDana NěmcováRichard MouyChristy SandborgJohn F BohnsackDirk ElewautChristos GabrielGloria HigginsIsabelle Kone-PautOlcay Y JonesVeronika VargováElizabeth ChalomCarine WoutersIvan LagunesYanna SongAlberto MartiniNicolino RupertoPublished in: RMD open (2021)
Through 6 years of exposure, adalimumab was well tolerated with significant clinical response (up to clinical remission) and a relatively low retention rate.